Next Article in Journal
Cytokinin-Controlled Gradient Distribution of Auxin in Arabidopsis Root Tip
Next Article in Special Issue
DYRK1A Negatively Regulates CDK5-SOX2 Pathway and Self-Renewal of Glioblastoma Stem Cells
Previous Article in Journal
The Zinc-Sensing Receptor GPR39 in Physiology and as a Pharmacological Target
Previous Article in Special Issue
Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma
 
 
Article

Enhancing Anti-Tumoral Potential of CD-NHF by Modulating PI3K/Akt Axis in U87 Ex Vivo Glioma Model

Regional Institute of Oncology, 2–4, General Henri Mathias Berthelot Street, 700483 Iasi, Romania
*
Author to whom correspondence should be addressed.
Academic Editor: Guillermo Gomez
Int. J. Mol. Sci. 2021, 22(8), 3873; https://doi.org/10.3390/ijms22083873
Received: 11 February 2021 / Revised: 6 April 2021 / Accepted: 7 April 2021 / Published: 8 April 2021
Background: In the latest years, there has been an increased interest in nanomaterials that may provide promising novel approaches to disease diagnostics and therapeutics. Our previous results demonstrated that Carbon-dots prepared from N-hydroxyphthalimide (CD-NHF) exhibited anti-tumoral activity on several cancer cell lines such as MDA-MB-231, A375, A549, and RPMI8226, while U87 glioma tumor cells were unaffected. Gliomas represent one of the most common types of human primary brain tumors and are responsible for the majority of deaths. In the present in vitro study, we expand our previous investigation on CD-NHF in the U87 cell line by adding different drug combinations. Methods: Cell viability, migration, invasion, and immunofluorescent staining of key molecular pathways have been assessed after various treatments with CD-NHF and/or K252A and AKTVIII inhibitors in the U87 cell line. Results: Association of an inhibitor strongly potentiates the anti-tumoral properties of CD-NHF identified by significant impairment of migration, invasion, and expression levels of phosphorylated Akt, p70S6Kinase, or by decreasing expression levels of Bcl-2, IL-6, STAT3, and Slug. Conclusions: Using simultaneously reduced doses of both CD-NHF and an inhibitor in order to reduce side effects, the viability and invasiveness of U87 glioma cells were significantly impaired. View Full-Text
Keywords: glioblastoma; anti-cancer agent; carbon dots; EMT; nanomedicine glioblastoma; anti-cancer agent; carbon dots; EMT; nanomedicine
Show Figures

Figure 1

MDPI and ACS Style

Luta, G.; Butura, M.; Tiron, A.; Tiron, C.E. Enhancing Anti-Tumoral Potential of CD-NHF by Modulating PI3K/Akt Axis in U87 Ex Vivo Glioma Model. Int. J. Mol. Sci. 2021, 22, 3873. https://doi.org/10.3390/ijms22083873

AMA Style

Luta G, Butura M, Tiron A, Tiron CE. Enhancing Anti-Tumoral Potential of CD-NHF by Modulating PI3K/Akt Axis in U87 Ex Vivo Glioma Model. International Journal of Molecular Sciences. 2021; 22(8):3873. https://doi.org/10.3390/ijms22083873

Chicago/Turabian Style

Luta, Gabriel, Mihail Butura, Adrian Tiron, and Crina E. Tiron. 2021. "Enhancing Anti-Tumoral Potential of CD-NHF by Modulating PI3K/Akt Axis in U87 Ex Vivo Glioma Model" International Journal of Molecular Sciences 22, no. 8: 3873. https://doi.org/10.3390/ijms22083873

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop